Cell and Gene Therapy

(SLA-052) Infection-Related Hospitalization After CAR-T Cell Therapy in Commercially Insured Patients with Hematologic Malignancies

(SLA-050) Mandated long-term follow-up studies of patients treated with gene and cell therapies approved in the European Union (EU): An analysis of commonalities and variations

(SLA-049) Post-approval Real-world Studies of RNA therapies in the EU: What Can We Learn from Study Characteristics?

(SLA-051) Role of the Regulatory Science Center in the Safety Management of Advanced Biological Products in Korea